Dr. Jonathan A. Schor

Dr. Schor is the Director of Vascular and Endovascular Surgery at Staten Island University Hospital and an Associate Professor of Surgery at Hofstra/Northwell School of Medicine. He is Board Certified in both Vascular and General Surgery. He completed his general surgical training at New York University and completed his vascular training at Rutgers/ New Jersey Medical School. Dr. Schor has participated in both clinical and basic science research that has been presented at local and national scientific meetings. He has a special interest in endovascular treatments of aortic aneurysm, peripheral vascular disease and venous disorders.Dr. Schor is co-director of the Staten Island University Hospital Aortic Center. The Aortic Center is a multi-specialty center for treatment of aortic pathology. He performed the first fully percutaneous treatment for abdominal aortic aneurysm on Staten Island in 2010. Dr. Schor also performed the first Transcarotid Artery Revascularization (TCAR) procedure on Staten Island for the treatment of carotid artery disease.Dr. Schor is interested in the treatment of peripheral vascular disease, venous disease and abdominal aortic aneurysm. Dr. Schor is a member of Society of Vascular Surgery, Eastern Vascular Society, American Venous Forum, and is a Fellow of the American College of Surgeons. He has a research interest in the surgical management of DVT and treatment of PVD. Dr. Schor is a principal investigator for a number of National Institute of Health (NIH) sponsored clinical research trials, and his research has been presented at both local and national meetings.

Dr. Schor is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Deep Vein Thrombosis, Necrosis, Thoracic Aortic Aneurysm, Carotid Artery Surgery, and Aneurysm Repair.

Dr. Schor is board certified in American Board Of Surgery and American Board Of Surgery/General-Vascular Surgery. He is actively involved in clinical research, co-authoring 25 peer reviewed articles and participating in 2 clinical trials.